Alzheimer's Disease Global Clinical Trials Review, H1, 2017

  • ID: 4239930
  • Clinical Trials
  • Region: Global
  • 833 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • AbbVi
  • Allergan Plc
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • MORE
Alzheimer's Disease Global Clinical Trials Review, H1, 2017

Summary

The clinical trial report, “Alzheimer's Disease Global Clinical Trials Review, H1, 2017" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVi
  • Allergan Plc
  • AstraZeneca Plc
  • Eisai Co Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • MORE
List of Tables
List of Figures
Report Guidance
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Alzheimer's Disease
Mar 20, 2017: Corium Reports Positive Progress in Pilot Bioequivalence Study of Once-Weekly Corplex Donepezil Patch
Mar 16, 2017: QR Pharma Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference
Mar 15, 2017: Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer's Disease
Mar 10, 2017: Nature Cell Started Commercial Clinical Trials Phase I and II ‘ASTROSTEM,’ Stem Cell Drug for Alzheimers Disease Treatment in US
Mar 08, 2017: TGA Regulatory Approval Received for Alzheimer’s Phase II Trial
Mar 08, 2017: Diabetes drug shows promise for safely treating, detecting Alzheimers disease
Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease
Mar 06, 2017: BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
Mar 06, 2017: MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease
Mar 01, 2017: Luye Pharma Group: Announcement Approval To Commence Clinical Trials For Rivastigmine Multi-Day Transdermal Patch In Germany
Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer's Therapy Crenezumab
Feb 28, 2017: Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer’s
Feb 19, 2017: BIIB076 Moves into Phase 1 for Alzheimer Disease
Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy
Feb 14, 2017: Cantabio Pharmaceuticals to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimers Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease
Feb 13, 2017: Alzheon to Present New Clinical Data and Analyses for ALZ-801 and Its Active Molecule Tramiprosate at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases
Feb 09, 2017: Xanamem research published in prestigious medical journal
Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment
Jan 26, 2017: New drug SAK3 may offer hope to Alzheimer's disease patients
Jan 25, 2017: ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria
Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
Jan 25, 2017: Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience
Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board
Jan 10, 2017: UK Regulatory Approval for Alzheimer's Disease Clinical Trial - XanADu
Jan 09, 2017: Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer’s disease patients
Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer’s Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers
Jan 03, 2017: FDA Approval to Commence Alzheimers Disease Clinical Trial
Dec 27, 2016: Investigational new drug for Alzheimer's scheduled for first study in humans
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact Us
Source

List of Tables
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017*
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017*
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017*
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017*
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer Inc
  • Johnson & Johnson
  • Eisai Co Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca Plc
  • Novartis AG
  • GlaxoSmithKline Plc
  • Allergan Plc
  • AbbVi
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll